| Monica L Brechtel, OT | |
|
19089 Florida Blvd, Albany, LA 70711-3603 | |
| (225) 209-7140 | |
| (225) 567-6847 |
| Full Name | Monica L Brechtel |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 19089 Florida Blvd, Albany, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275078750 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTT.Z11233 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Monica L Brechtel, OT Po Box 1536, Albany, LA 70711-1536 Ph: (225) 209-7140 | Monica L Brechtel, OT 19089 Florida Blvd, Albany, LA 70711-3603 Ph: (225) 209-7140 |
News Archive
Lippincott Williams & Wilkins announced today SUNY Downstate Medical Center, Brooklyn, New York, will provide the expert clinical content from Lippincott's Nursing Procedures and Skills to the nurses in their facility. Lippincott Williams & Wilkins is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy. SUNY Downstate Medical Center is one of the nation's leading urban medical centers, serving over 2.3 million people.
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.
In a comprehensive study released today by Population Action International (PAI) - an independent policy and research organization based in Washington, D.C. - the United States ranks 16th and receives a "C" on a list of 21 donor countries graded according to their financial and political support for international reproductive health and population programs.
Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.
› Verified 3 days ago
Eileen Willoughby, OT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 19089 Florida Blvd, Albany, LA 70711 Phone: 225-209-7140 Fax: 225-567-6847 |